What Will Cholera Vaccine Be Like in 100 Years?

Cholera is an acute intestinal infection that causes rapidly dehydrating diarrheal disease, which is caused by toxigenic serogroups of the bacterium Vibrio cholera. The disease is closely associated with poverty, poor sanitation, and lack of clean drinking water. Historically, devastating outbreaks of cholera resulted in millions of cases and hundreds of thousands of deaths. Currently, cholera remains an important public health problem in many countries, occurring as an endemic disease in some regions and causing major epidemics in some low-and middle-income countries (LMICs). The vaccine is used to control cholera and is mainly recommended for travelers and the people living in cholera-affected region. 

 Get PDF Brochure: https://bit.ly/2UydndX





The global cholera vaccine market is segmented based on product, end user, and region. Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. Depending on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.


Market Segment by Manufacturers includes:
Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., Johnson & Johnson (Crucell), Celldex Therapeutics, Inc., The other players in the value chain include (profiles not included in the report):, Merck & Co., Inc., GlaxoSmithKline plc.

Comments

Popular posts from this blog

For knowing more Luxury Goods

Latest Innovation Knocking-in Travel Pillow

Booming Growth in Air Compressor